Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL versus FOSAMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTONEL versus FOSAMAX.
ACTONEL vs FOSAMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and impairing osteoclast activity through inhibition of farnesyl pyrophosphate synthase.
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
70 mg orally once weekly for osteoporosis; 10 mg orally once daily for Paget's disease.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
Terminal elimination half-life is approximately 10.5 years in bone, reflecting slow release from the skeleton. Plasma half-life after intravenous administration is about 1 hour.
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Renal excretion of unchanged drug is the primary route (approximately 50% of absorbed dose). Unabsorbed drug is eliminated in feces. No biliary excretion.
Category C
Category C
Bisphosphonate
Bisphosphonate